drugset
drugset / Trial / NCT05426733

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

NCT05426733 ↗

Phase 3 Enrolling by invitation 180 enrolled Albireo, an Ipsen Company
NaSingle-groupOpen-labelTreatment

Summary

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia

Timeline

Start
2022-07-05
Primary completion
2028-06-30
Completion
2028-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Odevixibat Small molecule — Oral

Indications

biliary atresia